ArticleMolecular psychiatry2020
Activation of the mGlu
Open access · bronzeAbstract read
In one paragraph
Article in Molecular psychiatry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 50 citations in OpenAlex.
- ATAD3B and SKIL polymorphisms associated with antipsychotic-induced QTc interval change in patients with schizophrenia: a genome-wide association study.Translational psychiatry · 2022Trial
- Identifying drug targets for schizophrenia through gene prioritization.Translational psychiatry · 2026Article
- Overexpression of mGluMolecular neurobiology · 2025Article
- Characterization of Novel and Known Activators of Cannabinoid Receptor Subtype 2 Reveals Mixed Pharmacology That Differentiates Mycophenolate Mofetil and GW-842,166X from MDA7.International journal of molecular sciences · 2025Article
- Further Optimization of the mGluACS chemical neuroscience · 2025Article
- Psychosis of Epilepsy: An Update on Clinical Classification and Mechanism.Biomolecules · 2025Review
- Targeting Neuroplasticity in Substance Use Disorders: Implications for Therapeutics.Annual review of pharmacology and toxicology · 2025Review
- Discovery of VU6024578/BI02982816: An mGluJournal of medicinal chemistry · 2024Article
- Enriched Environment Contributes to the Recovery from Neurotoxin-Induced Parkinson's Disease Pathology.Molecular neurobiology · 2024Article
- The cannabinoid CBJournal of receptor and signal transduction research · 2024Article
- Evolutionary and functional analysis of metabotropic glutamate receptors in lampreys.Fish physiology and biochemistry · 2024Article
- Article
- Current Findings and Potential Mechanisms of KarXT (Xanomeline-Trospium) in Schizophrenia Treatment.Clinical drug investigation · 2024Review
- Lipid metabolism in dopaminergic neurons influences light entrainment.Journal of neurochemistry · 2023Article
- Cross-diagnostic determinants of cognitive functioning: the muscarinic cholinergic receptor as a model system.Translational psychiatry · 2023Review
- Positive Allosteric Modulation of mGluBiological psychiatry · 2022Article
- Allosteric Modulators of Metabotropic Glutamate Receptors as Novel Therapeutics for Neuropsychiatric Disease.Pharmacological reviews · 2022Review
- Metabotropic Glutamate Receptors As Emerging Targets for the Treatment of Schizophrenia.Molecular pharmacology · 2022Review
- mGluCell reports · 2021Article
- Neuronal metabotropic glutamate receptor 8 protects against neurodegeneration in CNS inflammation.The Journal of experimental medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Samantha E YohnDepartment of Pharmacology, Vanderbilt University, Nashville, TN, USA.
Daniel J FosterDepartment of Pharmacology, Vanderbilt University, Nashville, TN, USA.ORCID http://orcid.org/0000-0002-5225-354X
Dan P CoveyDepartment of Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, MD, USA.
Mark S MoehleDepartment of Pharmacology, Vanderbilt University, Nashville, TN, USA.ORCID http://orcid.org/0000-0002-8023-1313
Jordan GalbraithDepartment of Pharmacology, Vanderbilt University, Nashville, TN, USA.
Pedro M Garcia-BarrantesDepartment of Chemistry, Department of Biochemistry, Vanderbilt University, Nashville, TN, USA.
Hyekyung P ChoVanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN, USA.
Michael BubserDepartment of Pharmacology, Vanderbilt University, Nashville, TN, USA.
Anna L BlobaumVanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN, USA.
Max E JoffeDepartment of Pharmacology, Vanderbilt University, Nashville, TN, USA.
Joseph F CheerDepartment of Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, MD, USA.
Carrie K JonesDepartment of Pharmacology, Vanderbilt University, Nashville, TN, USA.
Craig W LindsleyDepartment of Pharmacology, Vanderbilt University, Nashville, TN, USA.
P Jeffrey ConnDepartment of Pharmacology, Vanderbilt University, Nashville, TN, USA. Jeff.Conn@Vanderbilt.edu.
Vanderbilt University · USUniversity of Maryland, Baltimore · US
Funding
REGULATION OF SIGNALING BY MGLUR5R01MH062646 · NIMH · VANDERBILT UNIVERSITY · PI P Jeffrey Conn, COLLEEN M NISWENDER · 2001 to 2026
$10.9MOverall: Eunice Kennedy Shriver Intellectual and Developmental Disabilities Research Center at VanderbiltP50HD103537 · NICHD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Jeffrey L Neul · 2020 to 2026
$10.3MResearch Project: Sensory and Multisensory Contributions to AutismU54HD083211 · NICHD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DYKENS, ELISABETH MAY · 2015 to 2019
$7.1MProgram in NeurogenomicsT32MH065215 · NIMH · VANDERBILT UNIVERSITY · PI ROGER J COLBRAN · 2002 to 2026
$6.4MFUNCTIONS OF METABOTROPIC GLUTAMATE RECEPTOR SUBTYPESR01NS031373 · NINDS · VANDERBILT UNIVERSITY · PI CONN, P JEFFREY · 1993 to 2025
$6.2MEndogenous Cannabinoid Control of Reward SubstratesR01DA022340 · NIDA · UNIVERSITY OF MARYLAND BALTIMORE · PI Joseph F Cheer · 2008 to 2026
$5.6MSafety and tolerability testing of VU0467319: an M1 PAM for clinical developmentU19MH106839 · NIMH · VANDERBILT UNIVERSITY · PI CONN, P JEFFREY · 2015 to 2017
$5.3MDiscovery of mGlu receptor PAMs for treatment of schizophreniaR01MH119673 · NIMH · VANDERBILT UNIVERSITY · PI CONN, P JEFFREY · 2019 to 2023
$3.6MFunctions of Metabotropic Glutamate Receptor SubtypesR37NS031373 · NINDS · VANDERBILT UNIVERSITY · PI CONN, P JEFFREY · 2014 to 2020
$3.5MEnduring Consequences of Adolescent Cannabinoid and Methylphenidate ExposureR01DA042595 · NIDA · UNIVERSITY OF MARYLAND BALTIMORE · PI CHEER, JOSEPH F · 2016 to 2020
$2.0MEndocannabinoid regulation of dopamine function and reinforcementF32DA041827 · NIDA · UNIVERSITY OF MARYLAND BALTIMORE · PI COVEY, DANIEL PATRICK · 2017 to 2018
$122kElucidation of mGlu1 Receptor Neurophysiology through use of Allosteric Modulators: Implications for the Treatment of SchizophreniaF32MH113266 · NIMH · VANDERBILT UNIVERSITY · PI YOHN, SAMANTHA · 2017 to 2018
$115kNICHD NIH HHS P50 HD103537NICHD NIH HHS U54 HD083211NIDA NIH HHS F32 DA041827NIDA NIH HHS R01 DA022340NIDA NIH HHS R01 DA042595NIMH NIH HHS F32 MH113266NIMH NIH HHS R01 MH062646NIMH NIH HHS R01 MH119673NIMH NIH HHS T32 MH065215NIMH NIH HHS U19 MH106839NINDS NIH HHS R01 NS031373NINDS NIH HHS R37 NS031373
Abstract
Recent clinical and preclinical studies suggest that selective activators of the M
Indexed as
Allosteric RegulationAnimalsAntipsychotic AgentsGlutamic AcidMiceMice, Inbred C57BLReceptor, Muscarinic M4Receptors, Metabotropic GlutamateAntipsychotic AgentsGlutamic AcidReceptor, Muscarinic M4Receptors, Metabotropic Glutamate
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.